论文部分内容阅读
目的:观察干扰素α(INF-α)联合胸腺肽治疗慢性己型肝炎(Chronic Hepatitis B,CHB)的疗效。方法:126例患者随机分为治疗组62例,给IFN-α 300万IU+胸腺肤20mg,均隔日1次;对照组64例,单用INF-α 300万IU,隔日1次,疗程均为6个月。主要观察患者治疗前后症状、体征、病毒复制指标、肝功能指标的变化。结果:①两组患者在主要症状、体征方面改善明显(x~2=7.45,P<0.05)。②疗程结束时及1年后,治疗组患者HBeAg及HBVDNA的阴转率均显著高于时照组(x~2=5.47、x~2=8.61,P<0.05、P<0.01)。结论:两药联用能明显抑制HBV复制,降低其反跳和病情复发。
Objective: To observe the curative effect of interferon α (INF-α) combined with thymosin in the treatment of Chronic Hepatitis B (CHB). Methods: One hundred and sixty-six patients were randomly divided into treatment group (n = 62) and IFN-α 3 million IU + thymus skin (n = 20) every other day. Control group (n = 64) received INF-α 3 million IU alone 6 months. The main observation before and after treatment of patients with symptoms, signs, viral replication indicators, liver function changes. Results: ①The improvement of the main symptoms and signs were obvious in both groups (x ~ 2 = 7.45, P <0.05). ② At the end of treatment and one year later, the negative conversion rates of HBeAg and HBVDNA in the treatment group were significantly higher than those in the control group (x ~ 2 = 5.47, x ~ 2 = 8.61, P <0.05, P <0.01). Conclusion: The combination of the two drugs can significantly inhibit HBV replication, reduce the rebound and the recurrence of the disease.